Cytokines and mucosal immunity

Current Opinion in Gastroenterology

Volumn 30, Issue 6, 2014, Pages 547-552

  Bamias, Giorgos ^a   Arseneau, Kristen O ^b   Cominelli, Fabio ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Inflammation; Innate lymphoid cells; Mucosal homeostasis

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 33; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CYTOKINE PRODUCTION; ENTERITIS; HUMAN; INNATE IMMUNITY; LYMPHOID CELL; MONONUCLEAR CELL; MUCOSAL IMMUNITY; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; HOMEOSTASIS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; CYTOKINES; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-23; INTERLEUKINS; INTESTINAL MUCOSA; SIGNAL TRANSDUCTION; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927611122     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000118     Document Type: Review

References (46)

1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.
2. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-1664.
3. Neurath MF, Finotto S. Translating inflammatory bowel disease research into clinical medicine. Immunity 2009;31:357-361.
4. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-342.
5. Bamias G, Corridoni D, Pizarro TT, et al. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012;59:451-459.
6. Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol 2013;4:181.
7. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011;140:1729-1737.
8. Fiocchi C. Early and late inflammatory bowel disease: why and how are they different? Curr Opin Gastroenterol 2011;27:317-320.
9. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007;23:365-369.
10. Bamias G, Martin C, Mishina M, et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005;128:654-666.
11. Spencer DM, Veldman GM, Banerjee S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002;122:94-105.
12. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGFbeta1-dependent tissue fibrosis in chronic 2, 4, 6-trinitrobenzene sulfonic acid colitis. J Immunol 2007;178:5859-5870.
13. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-1705.
14. Bluestone JA, Mackay CR, O'Shea JJ, et al. The functional plasticity of T cell subsets. Nat Rev Immunol 2009;9:811-816.
15. Fuchs A, Colonna M. Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract. Curr Opin Gastroenterol 2013;29:581-587.
16. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol 2013;13:75-87.
17. Bersudsky M, Luski L, Fishman D, et al. Nonredundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut 2014;63:598-609. This study dissects the roles of IL-1a and IL-1b in the setting of acute intestinal mucosal inflammation and repair.
18. Cominelli F, Nast CC, Llerena R, et al. Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest 1990;85:582-586.
19. van Heel DA, Ghosh S, Butler M, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005;365:1794-1796.
20. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009;41:71-76.
21. Bessa J, Meyer CA, de VeraMudry MC, et al. Altered subcellular localization of IL-33 leads to nonresolving lethal inflammation. J Autoimmun 2014. [Epub ahead of print] This study demonstrates the importance of subcellular localization of IL-33 for its release into the systemic circulation and its function as a proinflammatory alarmin.
22. Cohen I, Rider P, Carmi Y, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 2010;107:2574-2579.
23. Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 2011;44:265-278.
24. Sedhom MA, Pichery M, Murdoch JR, et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 2013;62:1714-1723.
25. Pushparaj PN, Li D, Komai-Koma M, et al. Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 2013;140:70-77.
26. Latiano A, Palmieri O, Pastorelli L, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One 2013;8:e62144.
27. Sattler S, Ling GS, Xu D, et al. IL-10-producing regulatory B cells induced by IL-33 (Breg (IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun 2014;50:107-122.
28. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-620.
29. Bamias G, Jia LG, Cominelli F. The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation. Curr Opin Gastroenterol 2013;29:597-602.
30. Bamias G, Kaltsa G, Siakavellas SI, et al. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Dig Liver Dis 2012;44:30-36.
31. Yu X, Pappu R, Ramirez-Carrozzi V, et al. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol 2014;7:730-740. This is the first demonstration that the TL1A/DR3 system of TNF-like factors is involved in the function of ILCs.
32. Meylan F, Hawley ET, Barron L, et al. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol 2014;7:958-968.
33. Liu C, Li XX, Gao W, et al. Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity. PLoS One 2014;9:e92743. This study provides evidence for a novel ligand for the receptor DR3 (TNFRSF25) that may also have therapeutic implications.
34. Jian J, Konopka J, Liu C. Insights into the role of progranulin in immunity, infection, and inflammation. J Leukoc Biol 2013;93:199-208.
35. Krause P, Zahner SP, Kim G, et al. The tumor necrosis factor family member TNFSF14 (LIGHT) is required for resolution of intestinal inflammation in mice. Gastroenterology 2014;146:1752-1762; e4.
36. Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014;20:313-318. An important study demonstrating in vivo for the first time that the efficacy of anti-TNF treatment in patients with IBD depends on the number of mucosal immunocytes expressing membrane TNF-a.
37. Perrier C, de Hertogh G, Cremer J, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013;19:246-253.
38. Zalevsky J, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007;179:1872-1883.
39. Bamias G, et al. Intestinal-specific TNFalpha overexpression induces Crohn'slike ileitis in mice. PLoS One 2013;8:e72594. This study shows that production of TNF-a by epithelial cells exclusively is sufficient to generate mucosal inflammation in mice.
40. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn's disease. Discov Med 2012;14:253-262.
41. Basu R, Hatton RD, Weaver CT. The Th17 family: flexibility follows function. Immunol Rev 2013;252:89-103.
42. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011;12:383-390.
43. Leung JM, et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 2014;7:124-133. This study provides direct proof for an important protective role of IL-22-producing CD4+ cells in the pathogenesis of acute mucosal inflammation.
44. Volpe E, Touzot M, Servant N, et al. Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production. Blood 2009;114:3610-3614.
45. Mielke LA, Jones SA, Raverdeau M, et al. Retinoic acid expression associates with enhanced IL-22 production by gammadelta T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med 2013;210:1117-1124. An important study that links retinoic acid with the production of IL-22 by gammadelta T cells and ILCs at the intestine.
46. Eken A, Singh AK, Treuting PM, et al. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol 2014;7:143-154.